NCT04898270View on ClinicalTrials.gov

Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

April 20, 2021

Conditions

Schizophrenia; PsychosisMetabolic SyndromeFlupentixolAntipsychotic AgentsCentral Nervous System DiseasesClinical TherapyOlanzapineQuetiapine

Interventions

DRUG

Flupentixol

"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity."

DRUG

Multi-acting receptor-targeted antipsychotics (MARTAs)

Trial Locations (1)

40705

Taichung Veterans General Hospital, Taichung

All Listed Sponsors

lead

Taichung Veterans General Hospital

OTHER

NCT04898270 - Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients | Biotech Hunter | Biotech Hunter